Xcout Intel
Curevo, Inc.
Curevo, Inc. is a biopharmaceutical company headquartered in Bothell, Washington. The company is focused on the research and clinical development of innovative vaccine technologies.
Subscribe to see Curevo, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Curevo, Inc. at a glance
Curevo, Inc. is a biotechnology company headquartered in United States. It has raised at least $192M across the 3 funding rounds on record. Its most recent funding round, Series B, raised $110M in March 2025. Xcout tracks 12 named people at Curevo, Inc., including Simeon George (CEO).
Curevo, Inc. leadership
- Simeon GeorgeCEO
- Gregory S. CurhanCFO
- Guy De La RosaCMO
- Andrea WangSr. VP CMC Operations
- David MillerVP, Strategic Communications
- Emma FritzenVP, Operations
6 more named people on record for Curevo, Inc., with roles, board committees and tenure — see the full roster →
Curevo, Inc. funding rounds
At least $192M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $110M | 8 named | |
| SEC Form D filing | $22M | — | |
| Series B | $60M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Curevo, Inc. news
Investors
Curevo, Inc. competitors
A few of Curevo, Inc.'s closest competitors — see the full list of competitors and alternatives →
Icosavax, Inc. is a Seattle, Washington-based clinical-stage biopharmaceutical company specializing in developing novel vaccines utilizing virus-like particle technology.
MalarVx, Inc. is a clinical-stage biopharmaceutical vaccine company located in Seattle, Washington, founded to develop innovative vaccines addressing global infectious diseases.
Aptevo Therapeutics Inc. is a public, clinical-stage biotechnology company headquartered in Seattle, Washington, focused on developing novel bispecific and trispecific immunotherapies for immuno-oncology.
Umoja Biopharma is a biotechnology research company headquartered in Seattle, Washington, focused on developing next-generation immunotherapies.
Deverra Therapeutics, Inc. is a private biotechnology company founded in 2015 and headquartered in Seattle, Washington, focused on developing drug pipelines and therapeutic solutions.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute myeloid leukemia and myelodysplastic syndromes. Beyond its lead asset, Aptevo's research pipeline encompasses several preclinical compounds. These include ALG.APV-527, an experimental bispecific ADAPTIR molecule designed to target both 4-1BB (CD137) and 5T4, a tumor-specific antigen prevalent in numerous cancer types. Another promising candidate is APVO603, a dual agonist bispecific antibody that targets both 4-1BB and OX40. The company is also advancing APVO442, a bispecific agent leveraging its ADAPTIR-FLEX platform technology to improve the precise delivery of drugs to prostate-specific membrane antigen (PSMA)-positive tumors for the treatment of prostate cancer. To further its development efforts for ALG.APV-527, Aptevo maintains a collaborative partnership and option agreement with Alligator Bioscience AB. Founded in 2016, Aptevo Therapeutics Inc. operates from its headquarters located in Seattle, Washington.
Get Curevo, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Curevo, Inc. in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access